U.S. flag An official website of the United States government
  1. Home
  2. For Consumers
  3. GuangDong NaiSiNiKe Information Technology Co Ltd. - www.themexicanpharmacyonline.com, and more
  1. Home

GuangDong NaiSiNiKe Information Technology Co Ltd. - www.themexicanpharmacyonline.com, and more

GuangDong NaiSiNiKe Information Technology Co Ltd. - www.themexicanpharmacyonline.com, and more

 Black HHS-Blue FDA Logo

 

October 23, 2018
 
To:
GuangDong NaiSiNiKe Information Technology Co Ltd.
7A-1, 7th Floor, No. 6 Jingyuan Road, Jida Industrial Zone
Zhuhai Guangdong 519015
China
 
Cc:
Verisign Global Registry Services
12061 Bluemont Way
Reston, VA 20190
 
 
The United States Food and Drug Administration is a consumer protection agency of the United States Government that is, among other things, responsible for regulating and supervising the safety of medical products and enforcing laws regulating medical products. Accordingly, we have determined that the website listed below is offering misbranded and unapproved new drugs, including opioids, for sale to consumers in the United States in violation of the Federal Food, Drug and Cosmetic Act (FD&C Act) found at Title 21, United States Code, § 321, 331, 352, 353 and 355, et. seq and the Controlled Substances Act found at Title 21, United States Code, § 841 et. seq.
 
The domain name below is registered by your company and is currently accessible to consumers in the United States:
 
 
These websites offer misbranded and unapproved new drugs for sale to U.S. consumers (e.g. letrozole, marketed as “Fempro” and “Zovirax Aciclovir” that is described as an “anti-herpes drug. While there are FDA-approved versions of Zovirax in the U.S. market, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the “Zovirax Aciclovir” product offered on the websites above). These products appear to be new drugs as defined by section 201(p) of the FD&C Act, 21 U.S.C. §321(p), because they are “not generally recognized as safe and effective.” Pursuant to section 505(a) of the Act, 21 U.S.C. §355(a), a new drug may not be introduced or delivered for introduction into interstate commerce unless it is the subject of an approved application. In addition, the introduction or delivery for introduction of such misbranded and unapproved new drug products into U.S. interstate commerce is a prohibited act per section 301 of the Act, 21 U.S.C. §321.
 
Furthermore, under U.S. law, prescription drugs can be dispensed only pursuant to a prescription from a healthcare practitioner licensed by law to administer prescription drugs. Offering for sale new drugs without requiring a prescription jeopardizes patient safety and misbrands the drug under section 503(b)(1) of the FD&C Act. Dispensing a prescription drug without a prescription is an act which results in the drug being misbranded while held for sale, in violation of section 301(k) of the FD&C Act (21 U.S.C. § 331(k)].
 
This is an abuse complaint submitted to you under Section 3.18.2 of the 2013 ICANN Registrar Accreditation Agreement (RAA) regarding the use of domain names for illegal purposes. The 2013 RAA contains requirements pertaining to your duty to investigate and respond appropriately to reports of illegal activity (Sections 3.18 and 1.13). An appropriate response to this complaint would be to ensure that this website is not able to sell or otherwise offer for sale any unapproved drugs or uncleared devices, or potentially counterfeit, controlled, adulterated or misbranded products to U.S. consumers in violation of U.S. law.
 
Thank you for your prompt attention to this matter. This abuse complaint is not intended to be an all-inclusive list of violations. Should your company or the registrant have any questions, please contact me at the contact information below.
 
 
Sincerely,
 
 
Health Fraud Branch
Office of Regulatory Affairs